Scholarlink

Background &amp; aims <p>Hepatitis B virus X protein (HBx) is a multifunctional viral regulator implicated in hepatocellular carcinoma (HCC). We aimed to characterize HBx mutations in liver tissue samples from Iranian patients with HCC and explore their potential structural and functional implications.</p> Methods <p>Liver tissue samples from 10 patients with HCC and chronic HBV infection were analyzed using high-resolution melting (HRM) and Sanger sequencing. Detected variants were assessed by phylogenetic analysis, 3D protein modeling, and STRING-based protein–protein interaction (PPI) mapping. Correlations with clinical and biochemical parameters were examined.</p> Results <p>Multiple HBx mutations were identified, including a novel nonsense mutation at codon 135 (G135*), resulting in C-terminal truncation. Additional substitutions were found in the H-box (V88A, K94E, A100T), BH3-like motif (L113P, Q116R, E122K, A126T), and CCCH zinc-binding domain (C61S, C69R). Structural modeling predicted that these variants may potentially disrupt DDB1 and Bcl-2 interactions, as well as zinc coordination. STRING analysis suggested altered HBx connectivity with TP53, BAX, TNF, IL6, and CREB1, potentially affecting apoptosis, transcriptional regulation, and inflammatory signaling. Phylogenetic analysis confirmed that variants clustered within genotype D1, indicating intra-genotypic adaptation. Clinically, higher viral loads and HBeAg positivity were associated with elevated liver injury markers, consistent with the predicted functional impacts of these variants.</p> Conclusions <p>HBx mutations in genotype D1, particularly the novel C-terminal truncation, may potentially influence viral persistence, apoptotic resistance, and oncogenic signaling in HCC, pending experimental validation. These findings highlight intra-genotypic HBx diversity as a potential biomarker and therapeutic target for HBV-related liver cancer.</p> Clinical trial number <p>Not applicable.</p> Graphical abstract <p> </p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Novel C-terminal HBx truncation (G135) in genotype D1 HBV: predicted effects on oncogenic signaling

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月28日

查看全文
  • Kamyar Mazloum Jalali,
  • Hamidreza Mollaei,
  • Chiman Karami,
  • Elahe Mosayebnejad Roudbaneh

摘要

Background & aims

Hepatitis B virus X protein (HBx) is a multifunctional viral regulator implicated in hepatocellular carcinoma (HCC). We aimed to characterize HBx mutations in liver tissue samples from Iranian patients with HCC and explore their potential structural and functional implications.

Methods

Liver tissue samples from 10 patients with HCC and chronic HBV infection were analyzed using high-resolution melting (HRM) and Sanger sequencing. Detected variants were assessed by phylogenetic analysis, 3D protein modeling, and STRING-based protein–protein interaction (PPI) mapping. Correlations with clinical and biochemical parameters were examined.

Results

Multiple HBx mutations were identified, including a novel nonsense mutation at codon 135 (G135*), resulting in C-terminal truncation. Additional substitutions were found in the H-box (V88A, K94E, A100T), BH3-like motif (L113P, Q116R, E122K, A126T), and CCCH zinc-binding domain (C61S, C69R). Structural modeling predicted that these variants may potentially disrupt DDB1 and Bcl-2 interactions, as well as zinc coordination. STRING analysis suggested altered HBx connectivity with TP53, BAX, TNF, IL6, and CREB1, potentially affecting apoptosis, transcriptional regulation, and inflammatory signaling. Phylogenetic analysis confirmed that variants clustered within genotype D1, indicating intra-genotypic adaptation. Clinically, higher viral loads and HBeAg positivity were associated with elevated liver injury markers, consistent with the predicted functional impacts of these variants.

Conclusions

HBx mutations in genotype D1, particularly the novel C-terminal truncation, may potentially influence viral persistence, apoptotic resistance, and oncogenic signaling in HCC, pending experimental validation. These findings highlight intra-genotypic HBx diversity as a potential biomarker and therapeutic target for HBV-related liver cancer.

Clinical trial number

Not applicable.

Graphical abstract